De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy by Sarah Moniz | Jan 18, 2018
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein by Adam | Oct 22, 2016Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]
